8-K
Next Technology Holding Inc. (NXTT)
View as plain text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 12, 2022
| WeTrade Group Inc. | ||
|---|---|---|
| (Exact name of Company as specified in charter) | ||
| Wyoming | 7374 | N/A |
| --- | --- | --- |
| (State or other jurisdiction of<br><br>incorporation or organization) | (Primary Standard Industrial<br><br>Classification Code Number) | (I.R.S. Employer<br><br>Identification Number) |
No 1 Gaobei South Coast, Yi An Men 111 Block 37, Chao Yang District,
Beijing City, People Republic of China 100020
+86-135-011-76409
(Address, including zip code, and telephone number, including area code, of principal executive offices)
Wyoming Registered Agent
1621 Central Ave Cheyenne, Wyoming 82001
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1, 99.2 and 99.3 attached, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| WETRADE GROUP INC. | ||
|---|---|---|
| Date: August 18, 2022 | By: | /s/ Pijun Liu |
| Name: | Pijun Liu | |
| Title: | CEO | |
| 3 | ||
| --- |
wtg_ex991.htm EXHIBIT 99.1
WeTrade Group Inc. Announces Strategic Cooperation with MobiLab Medical Innovatives Inc., globally launching an unparalleled and one-of-a-kind Monkeypox Virus testing kits with combined insurance coverage products
BEIJING, Aug. 16, 2022 /PRNewswire/ -- WeTrade Group Inc. (“WeTrade” or the “Company”) (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company has entered into a strategic cooperation exclusive service agreement (the “Agreement”) on August 15, 2022 with MobiLab Medical Innovatives (“MobiLab”) to launch a globally unparalleled and one-of-a-kind Monkeypox Virus testing kits with combined insurance coverage products with world-leading insurance companies. MobiLab is in the business of providing smart solutions for individuals and companies of all sizes self-screening tests covering a wide range of majoy diseases, infections, viruses. With MobiLab CEO Andrew Tang’s expertise and experience acquired from his more than 20 years career spearheading innovations in over 20 countries in the industry of insurance underwriting and health management, MobiLab has designed two unique insurance coverage products for the Monkeypox testing kits:
| 1) | Infectious disease insurance including losses caused by infectious diseases, covering certain percentage of the hospitalization and inpatient expense in the event of an insured diagnosed with Monkeypox; |
|---|---|
| 2) | Emergency care for hospitalization or critical illness covering Monkeypox hospitalization expense. |
Pursuant to the Agreement, MobiLab agreed to exclusively conduct in-depth introduction and coordination for WeTrade with several world leading insurance companies in the US, Europe and Asia, and help kicks off designing and structuring of unprecedented insurance products specially covering Monkeypox Virus patients that are tested positive with test kits distributed by WeTrade. MobiLab is committed to helping WeTrade expand into medical area where the cooperation with insurers will not only have a tremendous positive impact on WeTrade’s Monkeypox products, but also WeTrade’s other products on its own platform.
Wetrade and MobiLab are committed to saving lives and creating a healthier world, providing smart solutions for individuals and companies of all sizes and priding themselves on their unparalleled, dedicated service, including self-screening tests covering a wide range of major diseases, infections, viruses, and beyond. The cooperation between WeTrade and MobiLab will bridge the gap between symptoms and solutions. The cooperation will actively expand as they undergo the FDA approval process for a myriad of new at home tests.
Mr. Pijun Liu, Chief Executive Officer of the Company, commented, “After claiming our world-wide pioneer position in Monkeypox disease by securing exclusive global sales channel and a $50 million order recently, we are enthusiastic to work with MobiLab, thanks to its groundbreaking business in self-screening tests and its strong capability to help us connect with world-leading major insurance companies for Monkeypox testing kits with combined Insurance coverage products, which further consummates our spearheading position in Monkeypox testing and treatment. We expect the one-of-a-kind insurance coverage offered by Monkeypox testing kit products will bring us over US$100 million in revenue, given the considerable size of the potential market.”
About WeTrade Group Inc.
WeTrade Group Inc. is a technical service provider of SAAS and Cloud Intelligent System for micro-businesses, and a pioneer in offering internationalized system in the global micro-business cloud intelligence field and a leader, innovator and promoter of the world’s cloud intelligent system for micro-businesses. WeTrade Group independently developed the cloud intelligent system for micro-businesses (Abbreviation: YCloud). YCloud strengthens users’ marketing relationship and CPS commission profit management through leading technology and big data analysis. It also helps improve the payment scenarios to increase customers’ revenue by multi-channel data statistics, AI fission and management as well as improved supply chain system. As of today, YCloud’s business has successfully landed in mainland China and Hong Kong, covering the micro business industry, tourism industry, hospitality industry, livestreaming and short video industry, aesthetic medical industry and traditional retail industry. For more information, please visit https://ir.wetg.group.
Forward-Looking Statements
This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.
wtg_ex992.htm EXHIBIT 99.2
WeTrade Group Inc. Ready to kick-off a Strategic Partnership with Zhixun Bio through WeTrade’s SaaS platform and its the Internet of Things (IoT)
BEIJING, Aug. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. (“WeTrade” or the “Company”) (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company is in an advanced discussion with Zhixun Biotechnology Limited(“Zhixun”), a company who specializes in production of medical sterilization products. WeTrade and Zhixun are ready to launch an in-depth cooperative sales promotion of Zhixun’s disinfectant - Zhuchang in China and international markets, leveraging on WeTrade’s SaaS platform and its the Internet of Things (IoT) supply chain via government entities, hospitals, malls, and other medical distribution channels.
Zhuchang disinfectant is a portable spray, officially registered with the PRC government, being the only and one-of-a-kind product in the market that is able to completely eliminate the COVID-19 Omicron variant. Zhuchang disinfectant has passed three prevailing testing authorities in China, i.e. Hubei Center for Disease Control, Guangzhou Customs Technical Center and Zhongguancun International Pharmaceutical Inspection and Certification Institution.
Based on the above authorities’ research data, Zhuchang disinfectant can 100% eliminate the COVID-19 Omicron variant within one minute, and can get rid of other 99.99% common bacteria. This product has now completed the health and safety evaluation with PRC government, with complete approval for sales.
Mr. Pijun Liu, Chief Executive Officer of the Company, commented, “The potential partnership between Wetrade and Zhixun will not only enhance the sales of Zhixun’s one-of-a-kind disinfectant to the next level, but also expand Wetrade’s space in the medical area, which will become a strong and new growth driver for the Group. We firmly believe that the partnership between us and Zhixun will ultimately eliminate Omicron and bring our life and economy back to norm, making everyone’s life easier and more conformable.”
About WeTrade Group Inc.
WeTrade Group Inc. is a technical service provider of SAAS and Cloud Intelligent System for micro-businesses, and a pioneering internationalized system in the global micro-business cloud intelligence field and the leader, innovator and promoter of the world’s cloud intelligent system for micro-businesses. WeTrade Group independently developed the cloud intelligent system for micro-businesses (Abbreviation: YCloud). YCloud strengthens users’ marketing relationship and CPS commission profit management through leading technology and big data analysis. It also helps increase the payment scenarios to increase customers’ revenue by multi-channel data statistics, AI fission and management as well as improved supply chain system. As of today, YCloud’s business has successfully landed in mainland China and Hong Kong, covering the micro business industry, tourism industry, hospitality industry, livestreaming and short video industry, aesthetic medical industry and traditional retail industry. For more information, please visit https://ir.wetg.group.
Forward-Looking Statements
This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company’s encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.
wtg_ex993.htm EXHIBIT 99.3
WeTrade Group Inc. Announces US$50 Million Sales of Monkeypox Virus Test Kits to Parkway Medical Limited
BEIJING, Aug. 12, 2022 /PRNewswire/ -- WeTrade Group Inc. (“Wetrade” or the “Company”) (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company has entered into a sales agreement (the “Agreement”) on August 11, 2022 with Parkway Medical Limited (“Parkway Medical”) to sell monkeypox virus test kits and antigen tests for US$50 million.
Pursuant to the Agreement, Parkway Medical agreed to purchase 5 million units of nucleic acid test (RT-LAMP) and 6 million units of antigen tests (Colloidal Golden Technique) for an aggregate amount of US$50 million, and Parkway Medical has paid US$1 million as deposit.
Mr. Pijun Liu, Chief Executive Officer of the Company, commented, “We are excited about the sales of monkeypox virus kits and antigen tests to Parkway Medical after obtaining the exclusive sales channel from Jiqing Biomedical Technology Co. Ltd. It is important for us to be efficient so that we can take the lead to effectively tackle the challenges of the monkeypox outbreak. We are delighted to work with Parkway Medical to provide the test kits and antigen tests to overseas market as we aim to contribute to the prevention and control of the outbreak. With the support of our developed business ecosystem, we are optimistic about the future of Wetrade as it will definitely seize business opportunities and generate strong momentum for our growth.”
About WeTrade Group Inc.
WeTrade Group Inc. is a technical service provider of SAAS and Cloud Intelligent System for micro-businesses, and a pioneering internationalized system in the global micro-business cloud intelligence field and the leader, innovator and promoter of the world’s cloud intelligent system for micro-businesses. WeTrade Group independently developed the cloud intelligent system for micro-businesses (Abbreviation: YCloud). YCloud strengthens users’ marketing relationship and CPS commission profit management through leading technology and big data analysis. It also helps increase the payment scenarios to increase customers’ revenue by multi-channel data statistics, AI fission and management as well as improved supply chain system. As of today, YCloud’s business has successfully landed in mainland China and Hong Kong, covering the micro business industry, tourism industry, hospitality industry, livestreaming and short video industry, aesthetic medical industry and traditional retail industry. For more information, please visit https://ir.wetg.group.
Forward-Looking Statements
This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company’s encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.